Triggering of eryptosis, the suicidal erythrocyte death, by phenoxodiol.


Journal

Naunyn-Schmiedeberg's archives of pharmacology
ISSN: 1432-1912
Titre abrégé: Naunyn Schmiedebergs Arch Pharmacol
Pays: Germany
ID NLM: 0326264

Informations de publication

Date de publication:
10 2019
Historique:
received: 02 04 2019
accepted: 19 06 2019
pubmed: 8 7 2019
medline: 1 9 2020
entrez: 8 7 2019
Statut: ppublish

Résumé

Phenoxodiol is used for the treatment of malignancy. The substance is effective by triggering suicidal tumor cell death or apoptosis. At least in theory, phenoxodiol could similarly stimulate suicidal erythrocyte death or eryptosis. Eryptosis is characterized by cell shrinkage and breakdown of cell membrane asymmetry with phosphatidylserine translocation to the erythrocyte surface. Signaling of eryptosis includes increase of cytosolic Ca

Identifiants

pubmed: 31280326
doi: 10.1007/s00210-019-01681-8
pii: 10.1007/s00210-019-01681-8
doi:

Substances chimiques

Annexin A5 0
Antineoplastic Agents 0
Ceramides 0
Isoflavones 0
Reactive Oxygen Species 0
phenoxodiol 995FT1W541
Calcium SY7Q814VUP

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1311-1318

Commentaires et corrections

Type : ErratumIn

Références

Oncogene. 2003 May 1;22(17):2611-20
pubmed: 12730675
Am J Physiol Cell Physiol. 2003 Dec;285(6):C1553-60
pubmed: 14600080
Mol Hum Reprod. 2004 Jan;10(1):33-41
pubmed: 14665704
Oncol Res. 2004;14(11-12):567-78
pubmed: 15666998
Cell Death Differ. 2005 May;12(5):415-28
pubmed: 15746942
Cancer Res. 2005 Apr 15;65(8):3364-73
pubmed: 15833870
Int J Cancer. 2006 May 15;118(10):2412-20
pubmed: 16353157
Cancer. 2006 Feb 1;106(3):599-608
pubmed: 16388521
Curr Oncol Rep. 2006 Mar;8(2):104-7
pubmed: 16507219
Ann Oncol. 2006 May;17(5):860-5
pubmed: 16524966
Curr Opin Investig Drugs. 2006 Jun;7(6):542-8
pubmed: 16784025
Anticancer Drugs. 2006 Nov;17(10):1151-61
pubmed: 17075314
J Cell Biochem. 2007 May 15;101(2):295-306
pubmed: 17115410
J Transl Med. 2007 Jan 26;5:6
pubmed: 17257402
Cancer Biol Ther. 2007 Apr;6(4):612-7
pubmed: 17457041
Oncol Res. 2007;16(7):299-312
pubmed: 17518268
Biochem Pharmacol. 2007 Dec 3;74(11):1587-95
pubmed: 17904534
Methods Mol Biol. 2008;414:1-12
pubmed: 18175807
Future Oncol. 2008 Aug;4(4):475-82
pubmed: 18684059
Br J Cancer. 2009 Feb 24;100(4):649-55
pubmed: 19209173
Expert Opin Investig Drugs. 2009 Apr;18(4):469-79
pubmed: 19278301
Expert Opin Pharmacother. 2009 Apr;10(6):1059-67
pubmed: 19364253
Haematologica. 2009 Jul;94(7):928-34
pubmed: 19535345
Cell Physiol Biochem. 2009;24(3-4):133-40
pubmed: 19710527
Biofactors. 2008;34(3):253-60
pubmed: 19734127
J Cell Biochem. 2010 Aug 15;110(6):1504-11
pubmed: 20518072
Prostate. 2010 Aug;70(11):1211-21
pubmed: 20564423
Nutr Rev. 2010 Sep;68(9):542-55
pubmed: 20796219
Biochim Biophys Acta. 2011 Aug;1810(8):784-9
pubmed: 21571040
J Biosci. 2012 Mar;37(1):73-84
pubmed: 22357205
Mol Oncol. 2012 Aug;6(4):392-404
pubmed: 22583777
Am J Physiol Cell Physiol. 2012 Nov 1;303(9):C991-9
pubmed: 22954799
Toxins (Basel). 2013 Oct 23;5(10):1918-31
pubmed: 24152992
Cell Biochem Biophys. 2014 Nov;70(2):1337-42
pubmed: 24902539
Cancer Cell Int. 2014 Nov 08;14(1):110
pubmed: 25400509
Apoptosis. 2015 May;20(5):758-67
pubmed: 25637185
Bioorg Med Chem Lett. 2015 Nov 15;25(22):5377-83
pubmed: 26432036
Cell Physiol Biochem. 2016;39(4):1626-37
pubmed: 27626275
Cell Physiol Biochem. 2016;39(5):1977-2000
pubmed: 27771701
Cell Physiol Biochem. 2016;40(1-2):91-103
pubmed: 27855368
Curr Med Chem. 2017;24(9):937-942
pubmed: 27855617
Kidney Blood Press Res. 2017;42(4):749-760
pubmed: 29151105
Anticancer Res. 2018 Jan;38(1):301-306
pubmed: 29277787
FEBS J. 2019 Mar;286(5):826-854
pubmed: 30028073
Anticancer Res. 2018 Oct;38(10):5709-5716
pubmed: 30275191

Auteurs

Madeline Fink (M)

Department of Phamacology and Experimental Therapy, Eberhard-Karls-University of Tuebingen, Tübingen, Germany.

Abdulla Al Mamun Bhuyan (AAM)

Department of Phamacology and Experimental Therapy, Eberhard-Karls-University of Tuebingen, Tübingen, Germany.

Bernd Nürnberg (B)

Department of Phamacology and Experimental Therapy, Eberhard-Karls-University of Tuebingen, Tübingen, Germany.

Caterina Faggio (C)

Department of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, Viale Ferdinando Stagno d'Alcontres, S. Agata, Messina, Italy.

Florian Lang (F)

Department of Internal Medicine III, Eberhard-Karls-University of Tuebingen, Tübingen, Germany. florian.lang@uni-tuebingen.de.
Department of Vegetative & Clinical Physiology, University of Tübingen, 72074, Tübingen, Germany. florian.lang@uni-tuebingen.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH